Galmed Pharmaceuticals (GLMD) Competitors $1.37 0.00 (0.00%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.38 +0.01 (+0.73%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. RNAZ, ADXN, CDIO, BTAI, CARM, PRTG, BCLI, OBSV, IBIO, and AYTUShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include TransCode Therapeutics (RNAZ), Addex Therapeutics (ADXN), Cardio Diagnostics (CDIO), BioXcel Therapeutics (BTAI), Carisma Therapeutics (CARM), Portage Biotech (PRTG), Brainstorm Cell Therapeutics (BCLI), ObsEva (OBSV), iBio (IBIO), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. TransCode Therapeutics Addex Therapeutics Cardio Diagnostics BioXcel Therapeutics Carisma Therapeutics Portage Biotech Brainstorm Cell Therapeutics ObsEva iBio Aytu BioPharma TransCode Therapeutics (NASDAQ:RNAZ) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends. Does the media favor RNAZ or GLMD? In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 1 articles in the media. TransCode Therapeutics' average media sentiment score of 1.50 beat Galmed Pharmaceuticals' score of 0.00 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TransCode Therapeutics Very Positive Galmed Pharmaceuticals Neutral Which has higher valuation and earnings, RNAZ or GLMD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$18.55MN/AN/AGalmed PharmaceuticalsN/AN/A-$6.91M-$16.66-0.08 Do analysts rate RNAZ or GLMD? TransCode Therapeutics presently has a consensus target price of $280.00, indicating a potential upside of 3,426.45%. Given TransCode Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe TransCode Therapeutics is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor RNAZ or GLMD? Galmed Pharmaceuticals received 426 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 94.12% of users gave TransCode Therapeutics an outperform vote while only 62.25% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTransCode TherapeuticsOutperform Votes1694.12% Underperform Votes15.88%Galmed PharmaceuticalsOutperform Votes44262.25% Underperform Votes26837.75% Do institutionals and insiders hold more shares of RNAZ or GLMD? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is RNAZ or GLMD more profitable? Galmed Pharmaceuticals' return on equity of -28.75% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -649.03% -281.34% Galmed Pharmaceuticals N/A -28.75%-24.98% Which has more risk & volatility, RNAZ or GLMD? TransCode Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. SummaryTransCode Therapeutics and Galmed Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.27M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.088.9226.7619.71Price / SalesN/A252.24389.71117.54Price / CashN/A65.8538.2534.62Price / Book0.046.466.784.50Net Income-$6.91M$143.98M$3.23B$248.18M7 Day Performance8.73%2.03%1.51%0.23%1 Month Performance-6.80%4.11%10.03%12.39%1 Year Performance-71.28%-2.87%16.65%7.07% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals0.4114 of 5 stars$1.37flatN/A-70.7%$2.27MN/A-0.0820Upcoming EarningsGap DownRNAZTransCode Therapeutics2.2598 of 5 stars$0.36+4.5%$10.00+2,699.6%-100.0%$8.34MN/A0.009Positive NewsEarnings ReportADXNAddex Therapeutics1.6667 of 5 stars$7.77-4.1%$30.00+286.1%-5.6%$8.24M$556,045.00-22.8530Gap UpCDIOCardio Diagnostics2.5318 of 5 stars$0.16-15.0%$2.00+1,171.5%-79.4%$8.20M$34,890.000.001Earnings ReportBTAIBioXcel Therapeutics3.9462 of 5 stars$1.48-3.3%$42.60+2,778.4%-95.7%$8.12M$2.27M-0.0490CARMCarisma Therapeutics2.4833 of 5 stars$0.19+1.3%$1.93+897.4%-87.6%$8.07M$19.63M-0.1220PRTGPortage Biotech0.2925 of 5 stars$7.61-7.0%N/A+61.1%$7.98MN/A-0.186Gap DownBCLIBrainstorm Cell Therapeutics3.9706 of 5 stars$1.22+3.4%$30.00+2,359.0%-87.3%$7.96MN/A-0.2540Earnings ReportAnalyst ForecastGap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150IBIOiBio1.1676 of 5 stars$0.79+2.3%$4.30+443.3%-67.1%$7.82M$375,000.000.00100Gap UpHigh Trading VolumeAYTUAytu BioPharma1.8205 of 5 stars$1.26+0.8%N/A-35.7%$7.77M$77.23M-0.87160 Related Companies and Tools Related Companies RNAZ Competitors ADXN Competitors CDIO Competitors BTAI Competitors CARM Competitors PRTG Competitors BCLI Competitors OBSV Competitors IBIO Competitors AYTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLMD Stock Free GLMD Stock Alerts